Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Clinically meaningful tumor reduction rates vary by prechemotherapy MRI phenotype and tumor subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).

Mukhtar RA, Yau C, Rosen M, Tandon VJ; I-SPY 1 TRIAL and ACRIN 6657 Investigators., Hylton N, Esserman LJ.

Ann Surg Oncol. 2013 Nov;20(12):3823-30. doi: 10.1245/s10434-013-3038-y. Epub 2013 Jun 19.

2.

MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy?

McGuire KP, Toro-Burguete J, Dang H, Young J, Soran A, Zuley M, Bhargava R, Bonaventura M, Johnson R, Ahrendt G.

Ann Surg Oncol. 2011 Oct;18(11):3149-54. doi: 10.1245/s10434-011-1912-z. Epub 2011 Sep 27.

PMID:
21947592
3.

Analysis of factors that influence the accuracy of magnetic resonance imaging for predicting response after neoadjuvant chemotherapy in locally advanced breast cancer.

Ko ES, Han BK, Kim RB, Ko EY, Shin JH, Hahn SY, Nam SJ, Lee JE, Lee SK, Im YH, Park YH.

Ann Surg Oncol. 2013 Aug;20(8):2562-8. doi: 10.1245/s10434-013-2925-6. Epub 2013 Mar 6.

PMID:
23463090
4.

Tumor histological subtyping determined by hormone receptors and HER2 status defines different pathological complete response and outcome to dose-dense neoadjuvant chemotherapy in breast cancer patients.

Sánchez-Muñoz A, Plata-Fernández Y, Fernández M, Jaén-Morago A, Fernández-Navarro M, de la Torre-Cabrera C, Ramirez-Tortosa C, Pascual J, Alba E, Sánchez-Rovira P.

Clin Transl Oncol. 2014 Jun;16(6):548-54. doi: 10.1007/s12094-013-1116-z. Epub 2013 Oct 2.

PMID:
24085576
5.

Pathologic response to short intensified taxane-free neoadjuvant chemotherapy in patients with highly proliferative operable breast cancer.

Le Tourneau C, Dettwiler S, Beuzeboc P, Alran S, Laurence V, Pierga JY, Fréneaux P, Sigal-Zafrani B, Diéras V, Vincent-Salomon A.

Am J Clin Oncol. 2012 Jun;35(3):242-6. doi: 10.1097/COC.0b013e318209d34c.

PMID:
21358298
6.

Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017.

De Los Santos JF, Cantor A, Amos KD, Forero A, Golshan M, Horton JK, Hudis CA, Hylton NM, McGuire K, Meric-Bernstam F, Meszoely IM, Nanda R, Hwang ES.

Cancer. 2013 May 15;119(10):1776-83. doi: 10.1002/cncr.27995. Epub 2013 Feb 21.

7.

High expression of post-treatment Ki-67 status is a risk factor for locoregional recurrence following breast-conserving surgery after neoadjuvant chemotherapy.

Yamazaki N, Wada N, Yamauchi C, Yoneyama K.

Eur J Surg Oncol. 2015 May;41(5):617-24. doi: 10.1016/j.ejso.2015.01.036. Epub 2015 Mar 2.

PMID:
25771264
8.

The role of immunohistochemistry in breast cancer patients treated with neoadjuvant chemotherapy: an old tool with an enduring prognostic value.

Sánchez-Muñoz A, Plata-Fernández YM, Fernández M, Jaén-Morago A, Fernández-Navarro M, de la Torre-Cabrera C, Ramirez-Tortosa C, Lomas-Garrido M, Llácer C, Navarro-Perez V, Alba-Conejo E, Sánchez-Rovira P.

Clin Breast Cancer. 2013 Apr;13(2):146-52. doi: 10.1016/j.clbc.2012.11.006. Epub 2013 Jan 11.

PMID:
23318089
9.

The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy.

Straver ME, Rutgers EJ, Rodenhuis S, Linn SC, Loo CE, Wesseling J, Russell NS, Oldenburg HS, Antonini N, Vrancken Peeters MT.

Ann Surg Oncol. 2010 Sep;17(9):2411-8. doi: 10.1245/s10434-010-1008-1. Epub 2010 Apr 6.

10.

Combined neoadjuvant chemotherapy with bevacizumab improves pathologic complete response in patients with hormone receptor negative operable or locally advanced breast cancer.

Makhoul I, Klimberg VS, Korourian S, Henry-Tillman RS, Siegel ER, Westbrook KC, Hutchins LF.

Am J Clin Oncol. 2015 Feb;38(1):74-9. doi: 10.1097/COC.0b013e31828940c3.

PMID:
23563210
11.
12.

TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab.

Glück S, Ross JS, Royce M, McKenna EF Jr, Perou CM, Avisar E, Wu L.

Breast Cancer Res Treat. 2012 Apr;132(3):781-91. doi: 10.1007/s10549-011-1412-7. Epub 2011 Mar 4.

PMID:
21373875
13.

High expression of class III β-tubulin predicts good response to neoadjuvant taxane and doxorubicin/cyclophosphamide-based chemotherapy in estrogen receptor-negative breast cancer.

Wang Y, Sparano JA, Fineberg S, Stead L, Sunkara J, Horwitz SB, McDaid HM.

Clin Breast Cancer. 2013 Apr;13(2):103-8. doi: 10.1016/j.clbc.2012.11.003. Epub 2012 Dec 6.

14.

Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response.

Sánchez-Rovira P, Seguí MA, Llombart A, Aranda E, Antón A, Sánchez A, Lomas M, Jaén A, Fernández M, Porras I, Dalmau E, Morales S, de la Haba-Rodríguez J.

Clin Transl Oncol. 2013 Oct;15(10):810-7. doi: 10.1007/s12094-013-1006-4. Epub 2013 Feb 9.

15.

Prediction of pathological complete response to neoadjuvant chemotherapy by magnetic resonance imaging in breast cancer patients.

Michishita S, Kim SJ, Shimazu K, Sota Y, Naoi Y, Maruyama N, Kagara N, Shimoda M, Shimomura A, Noguchi S.

Breast. 2015 Apr;24(2):159-65. doi: 10.1016/j.breast.2015.01.001.

PMID:
25805427
16.

Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status.

Tanioka M, Sasaki M, Shimomura A, Fujishima M, Doi M, Matsuura K, Sakuma T, Yoshimura K, Saeki T, Ohara M, Tsurutani J, Watatani M, Takano T, Kawabata H, Mukai H, Naito Y, Hirokaga K, Takao S, Minami H.

Breast. 2014 Aug;23(4):466-72. doi: 10.1016/j.breast.2014.03.008. Epub 2014 Apr 16.

PMID:
24742606
17.

Preoperative evaluation of residual tumor extent by three-dimensional magnetic resonance imaging in breast cancer patients treated with neoadjuvant chemotherapy.

Akazawa K, Tamaki Y, Taguchi T, Tanji Y, Miyoshi Y, Kim SJ, Ueda S, Yanagisawa T, Sato Y, Tamura S, Noguchi S.

Breast J. 2006 Mar-Apr;12(2):130-7.

PMID:
16509837
18.

Patient and tumor characteristics associated with breast cancer recurrence after complete pathological response to neoadjuvant chemotherapy.

Ju NR, Jeffe DB, Keune J, Aft R.

Breast Cancer Res Treat. 2013 Jan;137(1):195-201. doi: 10.1007/s10549-012-2312-1. Epub 2012 Nov 13.

19.

Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.

Arslan UY, Turker I, Aksoy S, Oksuzoglu B, Helvaci K, Yildirim Ozdemir N, Uyeturk U, Uysal Sonmez O, Budakoglu B, Zengin N.

J BUON. 2013 Jul-Sep;18(3):585-93.

PMID:
24065468
20.

Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.

Kurebayashi J, Kanomata N, Yamashita T, Shimo T, Mizutoh A, Moriya T, Sonoo H.

Breast Cancer. 2015 May;22(3):292-9. doi: 10.1007/s12282-013-0478-y. Epub 2013 Jun 8.

PMID:
23749689

Supplemental Content

Support Center